title: STAT6 expression in glioblastoma promotes invasive growth.
abstract: BACKGROUND
  Glioblastoma (GBM) is a highly aggressive malignant primary brain tumor, characterized by rapid growth, diffuse infiltration of cells into both adjacent and remote brain regions, and a generalized resistance to currently available treatment modalities. Recent reports in the literature suggest that Signal Transducers and Activators of Transcription (STATs) play important roles in the regulation of GBM pathophysiology.
  
  
  METHODS
  STAT6 protein expression was analyzed by Western blotting in GBM cell lines and by immunohistochemistry in a tissue microarray (TMA) of glioma patient tissues. We utilized shRNA against STAT6 to investigate the effects of prolonged STAT6 depletion on the growth and invasion of two STAT6-positive GBM cell lines. Cell proliferation was assessed by measuring (3)H-Thymidine uptake over time. Invasion was measured using an in vitro transwell assay in which cells invade through a type IV collagen matrix toward a chemoattractant (Fetal Bovine Serum). Cells were then stained and counted. Kaplan-Meyer survival curves were generated to show the correlation between STAT6 gene expression and patient survival in 343 glioma patients and in a subset of patients with only GBM. Gene expression microarray and clinical data were acquired from the Rembrandt 1 public data depository (https://caintegrator.nci.nih.gov/rembrandt/). Lastly, a genome-wide expression microarray analysis was performed to compare gene expression in wild-type GBM cells to expression in stable STAT6 knockdown clones.
  
  
  RESULTS
  STAT6 was expressed in 2 GBM cell lines, U-1242MG and U-87MG, and in normal astrocytes (NHA) but not in the U-251MG GBM cell line. In our TMA study, STAT6 immunostaining was visible in the majority of astrocytomas of all grades (I-IV) but not in normal brain tissue. In positive cells, STAT6 was localized exclusively in the nuclei over 95% of the time. STAT6-deficient GBM cells showed a reduction in (3)H-Thymidine uptake compared to the wild-type. There was some variation among the different shRNA- silenced clones, but all had a reduction in (3)H-Thymidine uptake ranging from 35%- 70% in U-1242MG and 40- 50% in U-87MG cells. Additionally, STAT6- depleted cells were less invasive than controls in our in vitro transmembrane invasion assay. Invasiveness was decreased by 25-40% and 30-75% in U-1242MG and U-87MG cells, respectively. The microarray analysis identified matrix metalloproteinase 1 (MMP-1) and urokinase Plasminogen activator (uPA) as potential STA6 target genes involved in the promotion of GBM cell invasion. In a Kaplan-Meier survival curve based on Rembrandt 1 gene expression microarray and clinical data, there was a significant difference in survival (P < 0.05) between glioma patients with up- and down-regulated STAT6. Decreased STAT6 expression correlated with longer survival times. In two subsets of patients with either grade IV tumors (GBM) or Grade II/III astrocytomas, there was a similar trend that however did not reach statistical significance.
  
  
  CONCLUSIONS
  Taken together, these findings suggest a role for STAT6 in enhancing cell proliferation and invasion in GBM, which may explain why up-regulation of STAT6 correlates with shorter survival times in glioma patients. This report thus identifies STAT6 as a new and potentially promising therapeutic target.
authors: Department of Pathology, University of Virginia, Charlottesville, VA 22908, USA. bcm4u@virginia.edu
authors: Barbara C
authors: BC
authors: Merk
authors: Jennifer L
authors: JL
authors: Owens
authors: Maria-Beatriz S
authors: MB
authors: Lopes
authors: Corinne M
authors: CM
authors: Silva
authors: Isa M
authors: IM
authors: Hussaini
references: Pharmacol Ther. 2004 Apr;102(1):37-46
references: 15056497
references: Cancer Res. 2008 Jul 15;68(14):5955-64
references: 18632651
references: J Cell Sci. 2005 Apr 15;118(Pt 8):1629-39
references: 15784679
references: Chin Med J (Engl). 2006 May 20;119(10):801-8
references: 16732981
references: Cancer Res. 2007 Oct 15;67(20):9630-6
references: 17942891
references: Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13704-8
references: 8942998
references: J Neuropathol Exp Neurol. 2010 Jun;69(6):582-92
references: 20467333
references: Cancer Lett. 2009 Jan 8;273(1):164-71
references: 18793823
references: Mol Cancer Res. 2008 May;6(5):675-84
references: 18505913
references: Cell Mol Life Sci. 1999 Sep;55(12):1535-46
references: 10526571
references: Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13463-8
references: 19666510
references: Curr Opin Cell Biol. 2001 Apr;13(2):211-7
references: 11248555
references: Arterioscler Thromb Vasc Biol. 2000 Apr;20(4):931-9
references: 10764656
references: Science. 1995 Jul 7;269(5220):79-81
references: 7604283
references: FEBS Lett. 2003 Sep 11;551(1-3):8-12
references: 12965196
references: Science. 1997 Sep 12;277(5332):1630-5
references: 9287210
references: Endocr Relat Cancer. 2008 Jun;15(2):367-90
references: 18508994
references: Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9148-53
references: 8799169
references: J Immunol. 2000 Dec 1;165(11):6024-8
references: 11086033
references: Oncogene. 1999 Dec 2;18(51):7294-302
references: 10602484
references: Mol Cell Biol Res Commun. 2000 May;3(5):299-305
references: 10964754
references: J Exp Med. 1999 Jan 4;189(1):63-73
references: 9874564
references: Curr Opin Immunol. 1998 Jun;10(3):271-8
references: 9638363
references: J Neurooncol. 2011 Jun;103(2):267-76
references: 20845060
references: Oncogene. 2000 May 15;19(21):2474-88
references: 10851046
references: Gynecol Oncol. 2011 Feb;120(2):247-55
references: 21093894
references: Cancer Res. 2007 Nov 1;67(21):10241-51
references: 17974965
references: Cell. 1999 Aug 6;98(3):295-303
references: 10458605
references: Cancer Res. 2002 Feb 15;62(4):1103-9
references: 11861389
references: Curr Mol Med. 2009 Jun;9(5):626-33
references: 19601811
references: Cell Mol Life Sci. 1999 Sep;55(12):1547-58
references: 10526572
references: Clin Cancer Res. 2005 Dec 1;11(23):8288-94
references: 16322287
references: Nat Immunol. 2000 Dec;1(6):515-20
references: 11101874
references: Leukemia. 2009 Oct;23(10):1885-93
references: 19440213
references: BMC Cancer. 2003 Sep 17;3:23
references: 13678425
references: Expert Opin Investig Drugs. 2009 Apr;18(4):509-19
references: 19335279
references: Cancer Res. 2004 Nov 1;64(21):8126-9
references: 15520225
references: Biochem Biophys Res Commun. 2008 May 2;369(2):554-60
references: 18294957
references: Oncologist. 2006 Feb;11(2):152-64
references: 16476836
references: Blood. 2002 Jan 15;99(2):618-26
references: 11781246
references: J Biol Chem. 2000 Jul 21;275(29):22348-54
references: 10806212
references: Genes Chromosomes Cancer. 2010 Nov;49(11):981-90
references: 20665731
references: Clin Cancer Res. 2002 Apr;8(4):945-54
references: 11948098
references: Curr Opin Oncol. 2000 Nov;12(6):543-9
references: 11085453
references: Trends Mol Med. 2008 May;14(5):228-35
references: 18403264
references: J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):93-103
references: 18228120
references: Cancer Immunol Immunother. 2005 Nov;54(11):1137-42
references: 15877228
references: J Biol Chem. 2002 Jul 26;277(30):27169-75
references: 12023955
references: Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):419-23
references: 17683974
references: Oncogene. 2007 Apr 12;26(17):2435-44
references: 17043651
references: Neoplasia. 2005 Jun;7(6):545-55
references: 16036105
references: Cancer Biol Ther. 2008 Jul;7(7):997-1003
references: 18698165
references: J Immunol. 2002 Nov 15;169(10):5796-804
references: 12421960
references: J Immunol. 2000 Dec 1;165(11):6015-9
references: 11086031
references: Cancer Cell. 2005 Mar;7(3):207-8
references: 15766657
references: J Immunol. 2003 Feb 15;170(4):2014-21
references: 12574371
references: Exp Cell Res. 1999 Nov 25;253(1):63-77
references: 10579912
references: Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6
references: 11134512
references: Semin Radiat Oncol. 2009 Jul;19(3):163-70
references: 19464631
references: J Clin Invest. 2004 Sep;114(5):619-22
references: 15343379
references: J Neurooncol. 2008 Aug;89(1):9-17
references: 18415045
references: Oncogene. 2002 Mar 27;21(13):2058-65
references: 11960378
references: Crit Rev Oncol Hematol. 2006 Mar;57(3):245-53
references: 16213149
references: Blood. 2003 Apr 15;101(8):2940-54
references: 12480704
references: J Recept Signal Transduct Res. 1999 Jan-Jul;19(1-4):75-120
references: 10071751
references: Blood. 2005 Mar 15;105(6):2535-42
references: 15572583
references: J Urol. 2002 Apr;167(4):1859-62
references: 11912448
references: Mol Cell Biol. 1998 May;18(5):2545-52
references: 9566874
references: Semin Radiat Oncol. 2009 Jul;19(3):171-8
references: 19464632
references: Mol Cell Biol. 1999 May;19(5):3816-28
references: 10207105
references: N Engl J Med. 2005 Mar 10;352(10):987-96
references: 15758009
references: Curr Drug Targets. 2008 May;9(5):369-74
references: 18473764
references: Prostate. 2007 Oct 1;67(14):1550-64
references: 17705178
references: Blood. 2004 Jul 15;104(2):543-9
references: 15044251